Email ID
Password
Scrip   
US approves Lilly/Daiichi's prasugrel with boxed warning on bleeding
13 July 2009
Sue Sutter

The US FDA has approved Lilly/ Daiichi Sankyo's novel antiplatelet therapy Effient (prasugrel) to reduce the risk of thrombotic cardiovascular events, including stent thrombosis, in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention. The companies said they will launch...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36